IL2 and neoplasm: Remarkably, a heterotypic spheroid model composed of tumor cells, fibroblasts, and immune cells was developed to assess the efficacy of novel cancer immunotherapy agents [i.e., IL-2 variant and tumor- or fibroblast-targeted T cell bispecific antibody] both as monotherapy and in combination (110).